𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene

✍ Scribed by David J. Hughes; Sophie M. Ginolhac; Isabelle Coupier; Laure Barjhoux; Valérie Gaborieau; Brigitte Bressac-de-Paillerets; Agnès Chompret; Yves-Jean Bignon; Nancy Uhrhammer; Christine Lasset; Sophie Giraud; Hagay Sobol; Agnès Hardouin; Pascaline Berthet; Jean-Philippe Peyrat; Joelle Fournier; Catherine Nogues; Rosette Lidereau; Danièle Muller; Jean-Pierre Fricker; Michel Longy; Christine Toulas; Rosine Guimbaud; Drakoulis Yannoukakos; Sylvie Mazoyer; Henry T. Lynch; Gilbert M. Lenoir; David E. Goldgar; Dominique Stoppa-Lyonnet; Olga M. Sinilnikova

Publisher
John Wiley and Sons
Year
2005
Tongue
French
Weight
89 KB
Volume
117
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Marked variation in phenotypic expression among BRCA1 and BRCA2 mutation carriers may be partly explained by modifier genes that influence mutation penetrance. Variation in CAG/CAA repeat lengths coding for stretches of glutamines in the C‐terminus of the AIB1 protein (amplified in breast cancer 1, a steroid receptor coactivator) has been proposed to modify the breast cancer risk in women carrying germline BRCA1 mutations. We genotyped the AIB1 repeat length polymorphism from the genomic DNA of a group of 851 BRCA1 and 324 BRCA2 female germline mutation carriers to estimate an association with breast cancer risk modification. Hazard ratios (HR) were calculated using a Cox proportional hazards model. For BRCA1 and BRCA2 mutation carriers, analyzed separately and together, we found that women who carried alleles with 28 or more polyglutamine repeats had no increased risk of breast cancer compared to those who carried alleles with fewer repeats (HR for BRCA1/2 carriers = 0.88, 95% CI [confidence interval] = 0.75–1.04). Analyzing average repeat lengths as a continuous variable showed no excess risk of breast cancer (BC) in BRCA1 or BRCA2 mutation carriers (HR for average repeat length in BRCA1/2 carriers = 1.01, 95% CI = 0.92–1.11). These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Polyglutamine repeat length in the AIB1
Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers
✍ Luna Kadouri; Zsofia Kote-Jarai; Douglas F. Easton; Ayala Hubert; Rifat Hamoudi; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 84 KB 👁 1 views

## Abstract Variation in the penetrance estimates for __BRCA1__ and __BRCA2__ mutation carriers suggests that other factors may modify cancer risk from specific mutations. One possible mechanism is an epigenetic effect of polymorphisms in other genes. Genes involved in hormonal signal transduction

Coffee consumption and breast cancer ris
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers
✍ André Nkondjock; Parviz Ghadirian; Joanne Kotsopoulos; Jan Lubinski; Henry Lynch 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 91 KB 👁 1 views

## Abstract Although there are several plausible biologic mechanisms whereby coffee consumption might influence the risk of breast cancer, epidemiologic evidence is limited. We assessed the association between coffee consumption and breast cancer risk among high‐risk women who carry __BRCA__ mutati

BRCA1 and BRCA2 mutations in Russian fam
BRCA1 and BRCA2 mutations in Russian familial breast cancer
✍ Irina V. Tereschenko; Victoria M. Basham; Bruce A.J. Ponder; Paul D.P. Pharoah 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 24 KB 👁 2 views

We have screened index cases from 25 Russian breast/ovarian cancer families for germ-line mutations in all coding exons of the BRCA1 and BRCA2 genes, using multiplex heteroduplex analysis. In addition we tested 22 patients with breast cancer diagnosed before age 40 without family history and 6 patie

Ovarian cancer susceptibility alleles an
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
✍ Susan J. Ramus; Antonis C. Antoniou; Karoline B. Kuchenbaecker; Penny Soucy; Jon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of

Lymphocyte radiosensitivity in BRCA1 and
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility
✍ Julian Barwell; Laurent Pangon; Anne Georgiou; Ian Kesterton; Caroline Langman; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 336 KB

## Abstract There is conflicting evidence as to whether individuals who are heterozygous for germ‐line __BRCA1__ or __BRCA2__ mutations have an altered phenotypic cellular response to irradiation. To investigate this, chromosome breakage and apoptotic response were measured after irradiation in per

Germline mutations in the BRCA1 and BRCA
Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients
✍ A. Esra Manguoǧlu; Güven Lüleci; Tayfun Özçelik; Taner Çolak; Hagit Schayek; Mus 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB 👁 2 views

In this study we genotyped Turkish breast/ovarian cancer patients for BRCA1/BRCA2 mutations: protein truncation test (PTT) for exon 11 BRCA1 of and, multiplex PCR and denaturing gradient gel electrophoresis (DGGE) for BRCA2, complemented by DNA sequencing. In addition, a modified restriction assay w